Wageningen University
Wageningen, Gelderland, 6700 EV, Netherlands
NCT Number: NCT00110604
The purpose of this study is to determine if folic acid supplementation can slow down atherosclerotic progression, age-related cognitive decline and age-related hearing loss.
Looking for future studies?
Notify Me50 year–70 year
All sexes
Interventional
Not applicable
Wageningen, Gelderland, 6700 EV, Netherlands
Low levels of B vitamins, in particular folate, and high levels of plasma total homocysteine, have been associated with a variety of age-related diseases and disorders, including cardiovascular disease, dementia and hearing impairment. Extra folate, for example in the form of folic acid, is known to decrease the concentrations of plasma total homocysteine.
We examined whether 0.8 mg/d folic acid could slow down atherosclerotic progression and the above mentioned age-related processes.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Wageningen University
Other
The Folic Acid and Carotid Intima-Media Thickness (FACIT) Study: A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04181996
Arterial Occlusive Diseases, Arteriosclerosis
Edmonton, Alberta, Canada
View Trial DetailsNCT02685098
Amputation, Arterial Occlusive Disease
Indianapolis, Indiana, United States
View Trial DetailsNCT05436977
Acute Coronary Syndrome, Arterial Occlusive Diseases
Bologna, Italy
View Trial DetailsNCT03981380
Alzheimer Disease, Arterial Occlusive Diseases
New York, United States
View Trial Details